Clinical Research Forum named the BIOS CTCC study Early Outpatient COVID-19 Plasma Treatment Research Study (CSSC-004) one of the Top 10 2023 Clinical Research Achievement Awardees. The Clinical Research Achievement Awards is sponsored by the Clinical Research Forum, and it honors those who demonstrate a commitment to excellence and innovation in clinical research. This awards program seeks to recognize research that significantly advances health and welfare. The CSSC-004 trial will be recognized at an award ceremony in Washington, D.C., on April 17.
The CSSC-004 trial assessed the efficacy and safety of convalescent plasma to reduce the risk of hospitalization or death, the duration of symptoms, and duration of viral shedding through nasal and oral secretions. The study was led by researchers at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health with support and coordination from BIOS CTCC. The primary outcome data show that plasma from patients whose blood contains antibodies against SARS-CoV-2 is a safe and effective early outpatient treatment for COVID-19. Results were published in The New England Journal of Medicine.